Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating activities    
Net loss $ (41,443) $ (25,654)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 7,014 5,347
Amortization of investment premiums and discounts (217) 301
Depreciation and amortization expense 333 206
Non cash interest expense 64 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (189) 199
Other assets 160 (718)
Accounts payable (2,119) (466)
Accrued compensation (1,352) (1,136)
Accrued research and development expenses 2,330 (302)
Other current liabilities 544 179
Long-term liabilities 53 10
Net cash used in operating activities (34,822) (22,034)
Investing activities    
Purchases of short-term investments (292,467) (51,988)
Maturities of short-term investments 26,468 63,760
Sales of short-term investments 35,890 27,456
Purchases of property and equipment (19,808) (1,206)
Net cash provided by investing activities (249,917) 38,022
Financing activities    
Proceeds from sale of common stock in underwritten offerings, net 293,290 0
Proceeds from employee stock awards 6,186 0
Taxes paid related to net share settlement of restricted stock units (3,364) (326)
Principal payments on capital lease obligations (101) 0
Net cash provided by financing activities 296,011 (326)
Increase in cash, cash equivalents and restricted cash 11,272 15,662
Cash, cash equivalents and restricted cash at beginning of period 80,617 48,162
Cash, cash equivalents and restricted cash at end of period 91,889 63,824
Non-cash investing and financing activities    
Property and equipment purchases included in accounts payable and other accrued liabilities 4,105 207
Capitalized lease obligations 441 286
Interest capitalized during construction period for build-to-suit lease transaction 77 0
Asset retirement cost 88 0
Receivable for options exercised 10 0
Supplemental cash flow disclosure    
Cash paid for taxes $ 0 $ 2